603669 Stock Overview
Lionco Pharmaceutical Group Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in China.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Lionco Pharmaceutical Group Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥4.62 |
52 Week High | CN¥6.07 |
52 Week Low | CN¥2.94 |
Beta | 0.25 |
11 Month Change | -3.95% |
3 Month Change | -2.74% |
1 Year Change | -7.04% |
33 Year Change | -59.65% |
5 Year Change | -4.88% |
Change since IPO | -24.76% |
Recent News & Updates
Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
May 10There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 28% Price Jump
Mar 12Shareholder Returns
603669 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | 1.3% | 4.2% | -0.6% |
1Y | -7.0% | -10.6% | -22.0% |
Return vs Industry: 603669 exceeded the CN Pharmaceuticals industry which returned -10.6% over the past year.
Return vs Market: 603669 exceeded the CN Market which returned -22% over the past year.
Price Volatility
603669 volatility | |
---|---|
603669 Average Weekly Movement | 5.1% |
Pharmaceuticals Industry Average Movement | 5.1% |
Market Average Movement | 5.7% |
10% most volatile stocks in CN Market | 9.0% |
10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 603669 has not had significant price volatility in the past 3 months.
Volatility Over Time: 603669's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 475 | Ling Ping Tao | www.lingkang.com.cn |
Lionco Pharmaceutical Group Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in China. The company offers nutrition, antimicrobial, antiviral, digestion, cardiovascular, detoxification, anti-tumor, and other products. Lionco Pharmaceutical Group Co., Ltd.
Lionco Pharmaceutical Group Co.,Ltd. Fundamentals Summary
603669 fundamental statistics | |
---|---|
Market cap | CN¥3.25b |
Earnings (TTM) | -CN¥144.55m |
Revenue (TTM) | CN¥200.39m |
16.2x
P/S Ratio-22.5x
P/E RatioIs 603669 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
603669 income statement (TTM) | |
---|---|
Revenue | CN¥200.39m |
Cost of Revenue | CN¥115.33m |
Gross Profit | CN¥85.06m |
Other Expenses | CN¥229.60m |
Earnings | -CN¥144.55m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 24, 2024
Earnings per share (EPS) | -0.21 |
Gross Margin | 42.45% |
Net Profit Margin | -72.13% |
Debt/Equity Ratio | 50.9% |
How did 603669 perform over the long term?
See historical performance and comparison